Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Alpha fetoprotein targeted T cell therapy Adaptimmune (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man
  • Sponsors Adaptimmune
  • Most Recent Events

    • 06 Nov 2018 According to an Adaptimmune media release, dosing in Cohort 1 of this study is ongoing. Anticipate dose escalation to Cohort 2 in early 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 08 May 2018 Planned number of patients changed from 30 to 24.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top